Wells Fargo raised the firm’s price target on Medtronic to $102 from $100 and keeps an Overweight rating on the shares. Medtronic reported a broad-based beat for Q1 with organic revenue growth of 6% y/y on improving supply chain and end markets, as well as its pipeline ramping, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MDT:
- 3 Best Stocks to Buy Now, 8/23/2023, According to Top Analysts
- Medtronic ‘positioned to outperform’ after strong Q1, says Barclays
- Medtronic Stock (NYSE:MDT) Gained on Stellar Q1 Results
- Medtronic price target raised to $95 from $92 at Stifel
- Early notable gainers among liquid option names on August 22nd